Pegasus Laboratories, Inc. doing business as PRN® Pharmacal has announced the acquisition of Veterinary Products Laboratories' (VPL) animal health assets. VPL, a division of Central Life Sciences, is a companion animal health business focused on veterinary products including specialties in inflammation support, surgical suite supplies and house/yard parasite control. This acquisition will strengthen PRN's Pharmacal's product portfolio while expanding its reach into a number of therapeutic categories not previously serviced by the company.
"The addition of the VPL product lines to our pharmaceutical and nutritional portfolio is a natural fit as we continue to expand and grow," stated Donna Logan, Pegasus Laboratories' General Manager. "At PRN our goal is to serve veterinary niche markets and the underserved needs of the animal health community. With this acquisition we will be able to do this better than ever and for many years to come."
The purchase of VPL's animal health assets will include the following:
- Duralactin®
- Zentrol™
- Vet-Kem® family of products
- Monomend®, Polymend® and Chromend™ absorbable sutures
- NY-STA® and PRO-STA® non-absorbable sutures
- Tissumend II absorbable tissue adhesive
- Optima 365™
It will also include a continued partnership with Becton, Dickinson & Company (BD) to represent their surgical and medical device brands in the veterinary market.
"The VPL and PRN Pharmacal product lines complement each other and position the combined businesses for strategic growth opportunities," stated Betsy Watkins, Senior Director VPL. "The VPL sales team and I look forward to being a part of the PRN Pharmacal team to continue supporting our customers and leverage the strengths of both brands for the on-going success of the business," Watkins continued.